Sekundære endpoints omfattede andelen af patienter i klinisk remission i uge 4 (CDAI < 150) og den kliniske respons på længere sigt.
Secondary endpoints included the proportion of patients in clinical remission at week 4 (CDAI < 150) and clinical response over time.